Compare 3M Company (MMM) vs Revvity Inc (RVTY) Price & Performance

MMM trades at $182.04, showing modest daily weakness but maintaining a bullish technical trend with strong support near $181. Recent Q2 2026 earnings beat expectations with EPS of $2.40, driven by 5.4% organic growth and margin expansion, leading to raised full-year guidance. The stock's valuation remains elevated with a P/E of 32.53, while analyst sentiment is mixed with a near-even split between buy and hold ratings.

The outlook is cautiously optimistic, supported by operational improvements and innovation in high-growth verticals like Safety & Industrial. Key risks include litigation liabilities and macroeconomic pressures. Upside potential exists if execution continues to surpass expectations, but current prices may already reflect near-term gains.

RVTY trades at $115.18, down 0.72% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings of $1.41 per share, beating estimates, and raised its full-year outlook, driven by diagnostics strength and AI-enabled drug discovery. Revenue for 2025 was $2.86 billion with a net income margin of 8.16%, though valuation ratios like P/E of 55.64 appear elevated. Recent news includes product launches like the SuperFlex prenatal system and presentations at investor conferences.

The outlook is positive with analyst consensus favoring a buy rating and a $120.50 price target, suggesting upside. Key opportunities include robust diagnostics demand and innovation pipelines, while risks involve high valuation multiples and competitive pressures in the healthcare sector. Cash flow improved in 2026 to a net positive $31 million, supporting growth initiatives.